Social Media Ideas for Aquestive Therapeutics

Aquestive Resubmits Needle-Free Sublingual Epinephrine to FDA for Approval

Aquestive resubmits its Anaphylm NDA after completing additional human factors and pharmacokinetic studies requested by the FDA. The post Aquestive Resubmits Needle-Free Sublingual...

An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide

Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.

A Takeda spinout builds case for its Parkinson’s drug

Cerevance plans to meet with the FDA to “determine next steps” for a new kind of medicine known as solengepras, now that it has Phase 3 data in hand.

Aquestive Therapeutics moves R&D to HELIX in New Brunswick

The HELIX in downtown New Brunswick is maintaining momentum in October, announcing Aquestive Therapeutics Inc. has moved its research & development operations to the transforma...

<![CDATA[Viatris Acquires Pacira BioSciences for $1.65 Billion ]]>

Axsome rises on Auvelity prescription data

<![CDATA[Aptar and Aceso Therapeutics Enter Collaboration for Cystic Fibrosis Therapy ]]>

<![CDATA[Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Ente...

<![CDATA[METiS Enters Collaboration with Eli Lilly for Next-Generation Tissue-Specific LNP Delivery Technologies]]&gt...

<![CDATA[The Next Chapter in Metabolic Drug Development]]>

<![CDATA[Licensing Roundup: Biohaven & SK Biopharmaceuticals Enter Deal for BHV-7000, Haisco License’s Sentivera...

<![CDATA[Merck KGaA, Darmstadt, Germany, Acquires Silence Therapeutics for $1.3 Billion ]]>

Alembic Settles With Vanda Over Schizophrenia Drug Generic

Vanda Pharmaceuticals and Alembic Pharmaceuticals notified a Delaware federal judge Friday that they have settled a patent dispute over Alembic's planned generic version of Vanda's...

Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study

~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~

<![CDATA[ Eli Lilly to Acquire Merida Biosciences for $2.8 Billion ]]>

<![CDATA[Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreeme...

BioXcel files for Chapter 11, will sell assets to Teva

<![CDATA[M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz...

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Enters $2.8 Billion Agreement to Acquire Merida Biosciences]]>

Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal

Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental drug in a deal one analyst viewed as a “surprising...

<![CDATA[Roundup: Nanexa, Earendil Labs, and Atavistik Bio Enter Platform Deals with Novo Nordisk, Genentech, and Roc...

How J&J paved the way for Compass’ coming psychedelic drug launch

In an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the...

Pfizer-backed Priovant wins FDA approval for lead asset

Novartis Gains a Way to Get Drugs Into the Brain, Buying Sironax Tech for $125M

Novartis is acquiring a Sironax platform technology designed to transport a range of drug modalities across the protective blood-brain barrier. The deal comes as Novartis weathers...